전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved667 programs
ADCLimited DatastaleFudan UniversityPhase 2

Observational Cohort (Sacituzumab Tirumotecan, Sacituzumab Tirumotecan (Observational Cohort))

Bladder Cancer; Metastatic Urothelial Carcinoma · Bladder Cancer

#BladderCancer#ADC#Phase2#antibody-drug-conjugate#MetastaticUrothelialCarcinoma+1
Trials 1Status Recruiting
ADCLimited DatastaleSichuan Kelun-Biotech Biopharma…Phase 2

SKB264 (Sacituzumab Tirumotecan, Sacituzumab Tirumotecan (SKB264))

Advanced Biliary Tract Cancer(BTC) · Advanced Biliary Tract Cancer(BTC)

#AdvancedBiliaryTractCancerBTC#ADC#Phase2#antibody-drug-conjugate#Sichuan
Trials 1Status Recruiting
ADCLimited DatastaleThe First Affiliated Hospital o…Phase 2

sacituzumab govitecan (Trodelvy, Sacituzumab Tirumotecan Combined with Bevacizumab)

Platinum-resistant Recurrent Ovarian Cancer (PROC) · Platinum-resistant Recurrent Ovarian Can

#Platinum-resistantRecurrentOvari#ADC#Phase2#antibody-drug-conjugate#The
Trials 1Status Recruiting
ADCLimited DatastaleLi-kun ChenPhase 2

sacituzumab govitecan (Trodelvy, Sac-TMT, Sacituzumab tirumotecan, Sacituzumab tirumotecan (Sac-TMT) plus bevacizumab)

Lung Cancer · Lung Cancer

#LungCancer#ADC#Phase2#antibody-drug-conjugate#Li-kun
Trials 1Status Recruiting
ADCLimited DatastaleTianjin Medical University Canc…Phase 2

sacituzumab govitecan (Trodelvy, Sacituzumab tirumotecan combined with envafolimab)

Advanced Biliary Tract Cancers · Advanced Biliary Tract Cancers

#AdvancedBiliaryTractCancers#ADC#Phase2#antibody-drug-conjugate#Tianjin
Trials 1Status Recruiting
ADCLimited DatastaleTianjin Medical University Canc…Phase 2

sacituzumab govitecan (Trodelvy, Sacituzumab tirumotecan plus bevacizumab)

Lung Cancer · Lung Cancer

#LungCancer#ADC#Phase2#antibody-drug-conjugate#Tianjin
Trials 1Status Recruiting
AntibodyLimited DatastaleElevation OncologyPhase 2

Seribantumab (Seribantumab)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#Antibody#Phase2#monoclonal-antibody#Elevation
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 3

Serplulimab combined with bevacizumab and first-line chemotherapy (Serplulimab combined with bevacizumab and first-line chemotherapy)

Non-small Cell Lung Cancer Stage II; Bevacizumab · Non-small Cell Lung Cancer Stage II

#Non-smallCellLungCancerStageII#Antibody#Phase3#monoclonal-antibody#Bevacizumab+1
Trials 1Status Active
AntibodyLimited DatastaleFirst Affiliated Hospital of We…Phase 2

Serplulimab immunotherapy (Serplulimab immunotherapy)

Locally Advanced Rectal Cancer (LARC) · Locally Advanced Rectal Cancer (LARC)

#LocallyAdvancedRectalCancerLARC#Antibody#Phase2#monoclonal-antibody#First
Trials 1Status Recruiting
ADCLimited DatastaleRemeGen Co., Ltd.Phase 2

disitamab vedotin (Disitamab Vedotin, RC48, Short range radiotherapy with sequential Disitamab Vedotin combined with S-1 and xindilizumab)

Gastric Cancer · Gastric Cancer

#GastricCancer#ADC#Phase2#antibody-drug-conjugate#RemeGen
Trials 1Status Recruiting
AntibodyLimited DatastaleSun Yat-sen UniversityPhase 2

Sindilizumab (Sindilizumab)

Colorectal Cancer Metastatic; Chemotherapy · Colorectal Cancer Metastatic

#ColorectalCancerMetastatic#Antibody#Phase2#monoclonal-antibody#Chemotherapy+1
Trials 1Status Recruiting
AntibodyLimited DatastaleXin-Hua XuPhase 2

Sindillimab (Sindillimab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Xin-Hua
Trials 1Status Active
AntibodyLimited DatastaleInnoventPreclinical

pembrolizumab (Keytruda, MPA, Sintilimab or Pembrolizumab and medroxyprogesterone acetate, Sintilimab or Pembrolizumab and medroxyprogesterone acetate (MPA)/ megestrol acetate (MA))

Endometrial Cancer; Endometrioid Carcinoma · Endometrial Cancer

#EndometrialCancer#Antibody#Preclinical#monoclonal-antibody#EndometrioidCarcinoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 1

Siplizumab (Siplizumab)

T-Cell Peripheral Lymphoma; Gamma Delta Hepatosplenic T-Cell Lymphoma · T-Cell Peripheral Lymphoma

#T-CellPeripheralLymphoma#Antibody#Phase1#monoclonal-antibody#GammaDeltaHepatosplenicT-CellLym+1
Trials 1Status Active
AntibodyLimited DatastaleM.D. Anderson Cancer CenterPhase 2

Standard Dose Bevacizumab (Standard Dose Bevacizumab)

Brain Cancer; Glioblastoma · Brain Cancer

#BrainCancer#Antibody#Phase2#monoclonal-antibody#Glioblastoma+1
Trials 1Status Active
AntibodyLimited DatastaleAmsterdam UMC, location VUmcPhase 2

Standard dose cetuximab (Standard dose cetuximab)

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase2#monoclonal-antibody#Amsterdam
Trials 1Status Discontinued
AntibodyLimited DatastaleBeijing Chest HospitalPhase 2

Surufatinib Durvalizumab EP/EC (Surufatinib Durvalizumab EP/EC)

Extensive-stage Small-cell Lung Cancer · Extensive-stage Small-cell Lung Cancer

#Extensive-stageSmall-cellLungCan#Antibody#Phase2#monoclonal-antibody#Beijing
Trials 1Status Active
AntibodyLimited DatastaleUMC UtrechtPhase 2

FTD-TPI and bevacizumab (Systemic treatment, Systemic treatment (FTD-TPI and bevacizumab))

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase2#monoclonal-antibody#UMC
Trials 1Status Recruiting
AntibodyLimited DatastaleAgendiaApproved

trastuzumab (Herceptin, T + trastuzumab followed by CEF + trastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Approved#monoclonal-antibody#Agendia
Trials 1Status Active
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

T cells modified with RNA anti -cMET CAR (T cells modified with RNA anti -cMET CAR)

Malignant Melanoma; Breast Cancer · Malignant Melanoma

#MalignantMelanoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued

28 / 34 pages

← PreviousNext →